A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI). The study used the ...

Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose version of its diabetes drug liraglutide that can be used to treat obesity. The Danish ...

Emily McNutt is a journalist and editorial leader with extensive experience covering a range of topics from travel rewards to product reviews and financial news. With a passion for accurate reporting ...

Prescription drugs for obesity are gaining attention as lifestyle changes alone often fall short. Teva Pharmaceuticals (Teva) has launched the first generic glucagon-like peptide-1 (GLP-1) drug for ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...

Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s ...

(RTTNews) - Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Thursday said that the U.S. Food and Drug Administration (FDA) has approved a generic version of ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

PARSIPPANY, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S.

Saxenda (liraglutide) is one of eight FDA-approved drugs used for weight management. Saxenda is administered via injection with the Saxenda pen and works by decreasing hunger and appetite. While ...